Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1150 of 1631 entries
View as:

Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina

Phase: N/A Priority: Normal
NCT ID: NCT03784391 Org: User:
Start: 12/14/18 End: 04/06/20 Due: 04/06/21

Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02485119 Org: User:
Start: 08/14/15 End: 07/04/17 Due: 07/04/18

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

Phase: N/A Priority: Normal
NCT ID: NCT01890434 Org: User:
Start: 08/26/13 End: 11/10/16 Due: 11/10/17

Treatment of Hypertension With Adalat® in Combination With Other Drugs

Phase: N/A Priority: Normal
NCT ID: NCT01118286 Org: User:
Start: 01/31/10 End: 09/30/11 Due: 09/30/12

Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women

Phase: N/A Priority: Normal
NCT ID: NCT00651846 Org: User:
Start: 06/30/03 End: 02/28/05 Due: 02/28/06

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Phase: N/A Priority: Normal
NCT ID: NCT01947998 Org: User:
Start: 12/22/11 End: 09/30/20 Due: 09/30/21

NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)

Phase: N/A Priority: Normal
NCT ID: NCT01092858 Org: User:
Start: 09/30/10 End: 07/31/11 Due: 07/31/12

Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo

Phase: N/A Priority: Normal
NCT ID: NCT01940848 Org: User:
Start: 10/11/13 End: 10/25/17 Due: 10/25/18

Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

Phase: N/A Priority: Normal
NCT ID: NCT02368951 Org: User:
Start: 03/24/15 End: 07/27/16 Due: 07/27/17

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

Phase: N/A Priority: Normal
NCT ID: NCT03289273 Org: User:
Start: 09/13/17 End: 06/21/22 Due: 06/21/23

A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00492297 Org: User:
Start: 04/30/05 End: 07/31/08 Due: 07/31/09

GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients

Phase: N/A Priority: Normal
NCT ID: NCT01219582 Org: User:
Start: 10/31/10 End: 12/31/12 Due: 12/31/13

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01103323 Org: User:
Start: 04/30/10 End: 01/31/14 Due: 01/31/15

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Phase: N/A Priority: Normal
NCT ID: NCT00895674 Org: User:
Start: 07/31/06 End: 08/31/10 Due: 08/31/11

Sun Protection Factor Assay

Phase: N/A Priority: Normal
NCT ID: NCT02803047 Org: User:
Start: 11/09/15 End: 11/18/15 Due: 11/18/16

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

Phase: N/A Priority: Normal
NCT ID: NCT04147819 Org: User:
Start: 07/02/20 End: 09/26/23 Due: 09/26/24

Hepatocellular Carcinoma Registry for Turkey (3K Trial)

Phase: N/A Priority: Normal
NCT ID: NCT01473121 Org: User:
Start: 08/13/12 End: 07/12/18 Due: 07/12/19

BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00101413 Org: User:
Start: 04/30/04 End: 04/30/08 Due: 04/30/09

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02141438 Org: User:
Start: 08/20/14 End: 10/24/24 Due: 10/24/25

Dose Escalation Study of SH U04722 in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00375453 Org: User:
Start: 01/31/07 End: 10/31/07 Due: 10/31/08

A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.

Phase: N/A Priority: Normal
NCT ID: NCT04661917 Org: User:
Start: 05/31/21 End: 05/19/22 Due: 05/19/23

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00111007 Org: User:
Start: 05/31/05 End: 01/31/09 Due: 01/31/10

Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone

Phase: N/A Priority: Normal
NCT ID: NCT04232761 Org: User:
Start: 07/07/20 End: 04/29/24 Due: 04/29/25

18841- Sun Protection Factor Assay

Phase: N/A Priority: Normal
NCT ID: NCT02717351 Org: User:
Start: 03/16/16 End: 03/31/16 Due: 03/31/17

China Betaferon Adherence, Coping and Nurse Support Study

Phase: N/A Priority: Normal
NCT ID: NCT01436838 Org: User:
Start: 03/31/12 End: 12/31/15 Due: 12/31/16